Tue Aug 25, 2020 19:28
British Journal of Cancer, Published online: 27 August 2020; doi:10.1038/s41416-020-1021-5Evidence for hypoxia increasing the tempo of evolution in glioblastoma
03:00
Publication date: Available online 25 August 2020Source: Cancer/RadiothérapieAuthor(s): J. Jacob, N. Reyns, C.-A. Valéry, L. Feuvret, J.-M. Simon, J.-J. Mazeron, C. Jenny, M. Cuttat, P. Maingon, D. Pasquier
Wed Aug 26, 2020 13:14
Publication date: Available online 25 August 2020Source: Cancer/RadiothérapieAuthor(s): S. Thureau, A. Briens, P. Decazes, J. Castelli, A. Barateau, R. Garcia, J. Thariat, R. de Crevoisier
Wed Aug 26, 2020 13:14
Publication date: Available online 25 August 2020Source: Cancer/RadiothérapieAuthor(s): A. Rousselle, A. Amelot, J. Thariat, J. Jacob, G. Mercy, L. De Marzi, L. Feuvret
Wed Aug 26, 2020 13:14
Publication date: Available online 25 August 2020Source: Cancer/RadiothérapieAuthor(s): U. Schick, F. Lucia, V. Bourbonne, G. Dissaux, O. Pradier, V. Jaouen, F. Tixier, D. Visvikis, M. Hatt
Wed Aug 26, 2020 13:14
Purpose: Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macrophages. This Phase 1 study evaluated the immunologic and clinical activity, and safety profile of CSF-1R inhibition with the monoclonal antibody LY3022855. Experimental Design: Patients with advanced refractory metastatic breast cancer (MBC) or metastatic...
Wed Aug 26, 2020 16:13
Introduction: Itraconazole has been repurposed as an anti-cancer therapeutic agent for multiple malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits Hedgehog (Hh) pathway activity. We performed a window-of-opportunity trial to determine the biologic effects of itraconazole in human patients. Methods: Patients who had non-small cell lung cancer planned for surgical resection were administered 10-14 days of itraconazole 300 mg orally twice daily. Patients underwent...
Wed Aug 26, 2020 16:13
Recent work shows that TRAILshort, a membrane-bound short form of TRAIL, is expressed by human cancer cells and protects them from TRAIL-induced cell death. A monoclonal antibody that selectively targets TRAILshort enhances cancer susceptibility to TRAIL and increases the efficacy of autologous CD8+T cells in ex vivo primary tumours.
Wed Aug 26, 2020 16:13
Purpose: Docetaxel plays an indispensable role in the management of advanced prostate cancer (PCa). However, more than half of patients do not respond to docetaxel, and those good responders frequently experience significant cumulative toxicity, which limits its dose duration and intensity. Hence, a second agent that could increase the initial efficacy of docetaxel and maintain tolerability at biologically effective doses may improve outcomes for patients. Experimental Design: We determined phosphodiesterase...
Wed Aug 26, 2020 16:13
Publication date: Available online 26 August 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Gustavo Nader Marta, Charlotte Coles, Orit Kaidar-Person, Icro Meattini, Tarek Hijal, Yvonne Zissiadis, Jean-Philippe Pignol, Duvern Ramiah, Alice Y. Ho, Skye Hung-Chun Cheng, Gemma Sancho, Birgitte Vrou Offersen, Philip Poortmans
Wed Aug 26, 2020 12:53
Publication date: Available online 25 August 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Daniela Alterio, Irene Turturici, Stefania Volpe, Annamaria Ferrari, Samuel William Russell-Edu, Barbara Vischioni, Dikran Mardighian, Lorenzo Preda, Sara Gandini, Giulia Marvaso, Matteo Augugliaro, Stefano Durante, Simona Arculeo, Filippo Patti, Dario Boccuzzi, Alessia Casbarra, Anna Starzynska, Riccardo Santoni, Barbara Alicja Jereczek-Fossa
Wed Aug 26, 2020 12:53
Publication date: Available online 25 August 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Hadis Ghajari, Siamak Sabour
Wed Aug 26, 2020 12:53
Publication date: Available online 25 August 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Bo Zheng, Cristian Toarta, Wei Cheng, Monica Taljaard, Neil Reaume, Jeffrey J. Perry
Wed Aug 26, 2020 12:53
Publication date: October 2020Source: European Journal of Cancer, Volume 138Author(s): Tineke Vandenbroucke, Magali Verheecke, Mathilde van Gerwen, Kristel Van Calsteren, Michael J. Halaska, Monica Fumagalli, Robert Fruscio, Amarendra Gandhi, Margreet Veening, Lieven Lagae, Petronella B. Ottevanger, Jens-Uwe Voigt, Jorine de Haan, Mina M. Gziri, Charlotte Maggen, Luc Mertens, Gunnar Naulaers, Laurence Claes, Frédéric Amant, Jeroen Blommaert
Wed Aug 26, 2020 17:01
Publication date: Available online 26 August 2020Source: European Journal of Surgical OncologyAuthor(s): Pietro Achilli, Tyler S. Radtke, Jenna K. Lovely, Kevin T. Behm, Kellie L. Mathis, Scott R. Kelley, Amit Merchea, Dorin T. Colibaseanu, David W. Larson
Wed Aug 26, 2020 13:45
Abstract Many childhood cancer survivors (CCS) could benefit from improved knowledge about their cancer diagnosis, the treatments received, and associated risks during the period when they transition into adult aftercare. Interventions that support the transition from pediatric to adult care have showed high patient satisfaction. We developed an educational workbook, “Life After the Janeway,” to support CCS transition into adult care. We evaluated its understandability, actionability,...
Wed Aug 26, 2020 03:00
ABBV-321 (serclutamab talirine), a next-generation epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity matured AM1 antibody. ABBV-321 follows the development of related EGFR targeted ADCs including depatuxizumab mafodotin (depatux-m, ABT-414), ABT-806 conjugated to monomethyl auristatin F (MMAF), and ABBV-221 (losatuxizumab vedotin), AM1 antibody conjugated to...
Wed Aug 26, 2020 18:51
Purpose: To isolate circulating tumor cells (CTCs) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival (OS) and progression-free survival (PFS). Experimental Design: 7.5 mL of whole blood was drawn pre-cycle 1 and 36 days post-cycle 1 from patients enrolled on Gynecologic Oncology Group 0240, the phase III randomized trial that led directly to regulatory approval of the anti-angiogenesis drug, bevacizumab, in women with recurrent/metastatic...
Wed Aug 26, 2020 18:51
Rhabdoid tumor (RT) is an aggressive, early childhood tumor. Biallelic inactivation of the SMARCB1/INI1 gene is the only common genetic feature in RTs. Loss of SMARCB1 function results in down-regulation of several tumor suppressor genes including p16, p21, and NOXA. The novel histone deacetylase inhibitor OBP-801 induces p21 and has shown efficacy against various cancers. In our study, OBP-801 strongly inhibited the cell growth of all RT cell lines in WST-8 assay. However, western blotting and cell...
Wed Aug 26, 2020 18:51
Higher order DR5 clustering can induce tumor cell death, however therapeutic compounds targeting DR5 have achieved limited clinical efficacy. We describe HexaBody-DR5/DR5, an equimolar mixture of two DR5-specific IgG1 antibodies with an Fc-domain mutation that augments antibody hexamerization after cell surface target binding. The two antibodies do not compete for binding to DR5 as demonstrated using binding competition studies, and binding to distinct epitopes in the DR5 extracellular domain was...
Wed Aug 26, 2020 18:51
Development of antagonistic monoclonal antibodies that specifically target the immune checkpoint receptor, programmed cell death protein 1 (PD-1) is of great interest for cancer immunotherapy. Here we report the biophysical characteristics and non-clinical antagonistic activities of sasanlimab (PF-06801591), a humanized anti-PD-1 antibody of IgG4 isotype. We show that sasanlimab binds selectively and with similar high potency to human and cynomolgus monkey PD-1 receptor and blocks its interaction...
Wed Aug 26, 2020 18:51
Cancer stem cells (CSCs) are highly resistant to conventional chemotherapeutic drugs. YAP1 and STAT3 are the two transcription factors that facilitate the therapeutic resistance and expansion of CSCs. Our objective of this study is to understand the cross-talk between YAP1 and STAT3 activities and to determine the therapeutic efficacy of targeting dual CSC regulating pathways (YAP1 and STAT3) combined with chemotherapy in lung adenocarcinoma (LUAD). Here, we showed that YAP1 contributes to CSC regulation...
Wed Aug 26, 2020 18:51
CB-03-10 (cortexolone 17α-valerate-21-propionate) is a synthetic steroidal compound derived from cortexolone (11-deoxycortisone), an intermediate in cortisol biosynthesis. Characterization of the activity of CB-03-10 and its main related compound CB-03-05 (cortexolone 17α-valerate) included in vitro binding to the androgen and glucocorticoid receptors (AR and GR), antagonism of AR and GR transcriptional activities, and screening for antitumor activity across a selected panel of human prostate and...
Wed Aug 26, 2020 18:51
Loss of the tumor suppressor NF1 leads to activation of RAS effector pathways, which are therapeutically targeted by inhibition of mTOR (mTORi) or MEK (MEKi). However, therapeutic inhibition of RAS effectors leads to the development of drug resistance and ultimately disease progression. To investigate molecular signatures in the context of NF1 loss and subsequent acquired drug resistance we analyzed the exomes, transcriptomes and kinomes of Nf1 mutant mouse tumor cell lines and derivatives of these...
Wed Aug 26, 2020 18:51
Paternally Expressed Gene 10 (PEG10) has been associated with neuroendocrine (NE)-muscle-invasive bladder cancer (MIBC), a subtype of the disease with the poorest survival. In this work, we further characterized the expression pattern of PEG10 in TCGA database of 412 MIBC pateints, and found that, compared to other subtypes, PEG10 mRNA level was enhanced in NE-like MIBC and highly correlats with other NE markers. PEG10 protein level also associated with NE markers in a tissue microarray (TMA) of...
Wed Aug 26, 2020 18:51
Vascular endothelial growth factor (VEGF) blockade does not uniformly result in clinical benefit. We evaluated safety, dose-limiting toxicities (DLTs), recommended phase II dose (RP2D), antitumor efficacy, and exploratory biomarkers including pharmacogenomics and pharmacokinetics with sorafenib, bevacizumab and paclitaxel in refractory cancer patients. The study had a "3+3" design, using paclitaxel 80 mg/m2 QW x 3 every 4 weeks, bevacizumab 5 mg/kg Q2W, and sorafenib 200 or 400 mg BID, 5 or 7 days/week...
Wed Aug 26, 2020 18:51
Currently, most patients with non-small cell lung cancer (NSCLC) are diagnosed in advanced stages with a poor five-year survival rate. Therefore, intensive research aimed at finding novel therapeutic strategies has been ongoing; experimental models that reliably emulate NSCLC disease are greatly needed to predict responses to novel therapeutics. Therefore, we developed patient-derived xenograft models of NSCLC, which we then used to evaluate the therapeutic efficacy of 177Lu-EB-RGD, a peptide-based...
Wed Aug 26, 2020 18:51
Measles viruses (MV) are rapidly inactivated by anti-measles neutralizing antibodies which has limited their clinical performance as oncolytic agents. Here, by substituting the H and F surface glycoproteins of MV with those from the homologous canine distemper virus (CDV) and engineering the CDV H attachment protein to target EGF receptor or CD38, we generated a fully retargeted MV capable of resisting neutralization by measles-immune human serum. The resultant recombinant MVs encoding retargeted...
Wed Aug 26, 2020 18:51
Effective treatments for chemotherapy-induced peripheral neuropathy (CIPN) remain unavailable. Given the significance of spinal cord glutamate transporters in neuronal plasticity and central sensitization, this study investigated the role of excitatory amino acid transporter 2 (EAAT2) and vesicular-glutamate transporter 2 (VGLUT2) in the development of paclitaxel-induced painful neuropathy. Paclitaxel (2 mg/kg, i.p., cumulative dose 8mg/kg) induced long-lasting mechanical allodynia (> 28days)...
Wed Aug 26, 2020 18:51
Direct cell death induction, in addition to immune effector cell-mediated mechanisms, is one of the key mechanisms of action of anti-CD20 antibodies and yet the signaling pathways implicated remain poorly investigated. Here we show that the transcription factor EGR-1 is rapidly induced by anti-CD20 antibodies and is a key mediator for CD20-induced cell death. EGR-1 induction results from an increased calcium influx induced by anti-CD20 antibodies. We show that both rituximab and obinutuzumab induce...
Wed Aug 26, 2020 18:51
The sole inhibitory Fc receptor CD32b (FcRIIb) is expressed throughout B and plasma cell development and on their malignant counterparts. CD32b expression on malignant B cells is known to provide a mechanism of resistance to Rituximab that can be ameliorated with a CD32b-blocking Ab. CD32b therefore represents an attractive tumor antigen for targeting with a monoclonal Ab (mAb). To this end, two anti-CD32b mAbs, NVS32b1 and NVS32b2, were developed. Their complementarity-determining regions (CDRs)...
Wed Aug 26, 2020 18:51
Abstract Objective To assess the extent to which spiritual well‐being moderates the relationship between anxiety and physical well‐being in a diverse, community‐based cohort of newly diagnosed cancer survivors. Methods Data originated from the Measuring Your Health (MY‐Health) study cohort (n=5506), comprised of people assessed within 6‐13 months of cancer diagnosis. Life meaning/peace was assessed using the 8‐item subscale of the Spiritual Well‐Being Scale (FACIT‐Sp‐12). Anxiety was measured...
Tue Aug 25, 2020 16:40
Abstract Objective Despite its high prevalence, cancer‐related insomnia typically remains untreated because of a lack of access to cognitive‐behavioral therapy for insomnia (CBT‐I), the treatment of choice for this condition. While face‐to‐face CBT‐I appears to be optimal in terms of efficacy, self‐administered formats may be more cost‐effective. The goal of this secondary analysis of a randomized clinical trial was to compare the cost‐effectiveness of a professionally‐based CBT‐I (PCBT‐I) to...
Tue Aug 25, 2020 16:36
Abstract Purpose This study aimed to explore work ability (WA) in breast cancer (BC) survivors and to examine the mechanism by which perceived emotional intelligence (PEI) acts as a covitality factor that preserves WA and promotes the return to work in this clinical population. Methods The sample was composed of 622 women divided into two groups: BC survivors (6.75%) and healthy controls (93.25%). Participants completed the Work Ability Index and Trait‐Meta‐Mood Scales. Descriptive statistical...
Tue Aug 25, 2020 16:36
Abstract Objective This qualitative study sought to obtain feedback from stakeholder cancer caregivers and bereaved family members on the implementation of bereavement risk screening in oncology. Methods Semi‐structured interviews were conducted with 38 family members of patients with advanced cancer (n=12) and bereaved family members (n=26) on when and how to effectively implement bereavement risk screening. Data was analyzed using thematic analysis. Results Many participants indicated...
Tue Aug 25, 2020 16:32
Abstract Objective Shared decision‐making, including the elicitation of patient preferences regarding treatment decisions, is considered part of high‐quality cancer care. However, patients may not be able to self‐report due to illness, and therefore proxy reports may be used. We sought to determine the difference between proxy and patient reports about patient decisions and preferences among patients who received or were scheduled for chemotherapy using data from a large, population‐based survey...
Tue Aug 25, 2020 16:31
Publication date: Available online 25 August 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Yoshihiro Ueda, Hajime Monzen, Jun-ichi Fukunaga, Shingo Ohira, Mikoto Tamura, Osamu Suzuki, Shoki Inui, Masaru Isono, Masayoshi Miyazaki, Iori Sumida, Kazuhiko Ogawa, Teruki Teshima
Wed Aug 26, 2020 15:05
Publication date: Available online 25 August 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Ondrej Sorejs, Milos Pesek, Jindrich Finek, Ondrej Fiala
Wed Aug 26, 2020 15:05
Publication date: Available online 25 August 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): James M. Jurica, Jay A. Messer, Bin S. Teh, Brian E. Butler, Andrew M. Farach
Wed Aug 26, 2020 15:05
Publication date: Available online 25 August 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Jose Antonio Solis Campos, Gabriel Antonio Veillon Contreras, Benjamin Tobias Tudela Staub
Wed Aug 26, 2020 15:05
Publication date: Available online 25 August 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Shearwood McClelland, Vivek Verma
Wed Aug 26, 2020 15:05
Publication date: Available online 25 August 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Amal Rayan, Samya Abdel-Kareem, Huda Hasan, Asmaa M. Zahran, Doaa A. Gamal
Wed Aug 26, 2020 15:05
Exoribonuclease-resistant RNAs (xrRNAs) are discrete elements that block the progression of 5’ to 3’ exoribonucleases using specifically folded RNA structures. A recently discovered class of xrRNA is widespread in several genera of plant-infecting viruses, within both noncoding and protein-coding subgenomic RNAs. The structure of one such xrRNA from a dianthovirus revealed three-dimensional details of the resistant fold but did not answer all questions regarding the conservation and diversity of...
Wed Aug 26, 2020 19:05
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου